MedTrace Logo

Calcitonin Gene-related Peptide in Familial Hemiplegic Migraine (FHM) and Migraine With Aura (MA)

NCT00687947 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2009-08-03

No results posted yet for this study

Summary

The aim of the present study is to explore the importance of migraine phenotype on the headache/migraine responses after CGRP in FHM-patients, MA-patients and healthy volunteers.

Conditions

  • Familial Hemiplegic Migraine
  • Migraine With Aura
  • Healthy

Interventions

DRUG

CGRP

CGRP (0.5 ug/min) infused intravenously over 20 min

Sponsors & Collaborators

  • EUROHEAD

    collaborator OTHER

  • Danish Headache Center

    lead OTHER

Principal Investigators

  • Jakob Møller Hansen, MD · Danish Headache Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2008-08-31
Completion
2008-08-31

Countries

  • Denmark

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00687947 on ClinicalTrials.gov